topotecan + lurbinectedin

**topotecan + lurbinectedin** is an investigational combination of two small-molecule antineoplastic agents under evaluation primarily for the treatment of small cell lung cancer (SCLC) and potentially other solid tumors. - **Topotecan** is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the topoisomerase I-DNA complex, resulting in DNA strand breaks and cell death. - **Lurbinectedin** is a synthetic analog of trabectedin that covalently binds DNA in the minor groove, causing double-strand breaks, disrupting DNA-protein interactions and RNA transcription, and modulating the tumor microenvironment via apoptotic activity on peripheral blood monocytes and tumor-associated macrophages, and inhibition of inflammatory chemokine expression and angiogenesis[2][3]. Clinical trials have evaluated the combination (and lurbinectedin in comparison to topotecan), with lurbinectedin showing favorable efficacy and toxicity profiles compared to topotecan in relapsed SCLC; however, as a combination regimen, published data are limited and trials such as ATLANTIS have primarily compared lurbinectedin plus doxorubicin vs topotecan-based regimens[2]. The combination is delivered intravenously and is being investigated in patients who have failed prior platinum-containing therapy[2].

Other names

topotecan + lurbinectedin